P-cresol alters brain dopamine metabolism and exacerbates autism-like behaviors in the BTBR mouse by PASCUCCI, Tiziana et al.
 
Brain Sci. 2020, 10, 233; doi:10.3390/brainsci10040233 www.mdpi.com/journal/brainsci 
Article 
P-cresol Alters Brain Dopamine Metabolism  
and Exacerbates Autism-Like Behaviors  
in the BTBR Mouse 
Tiziana Pascucci 1,2, Marco Colamartino 1,2, Elena Fiori 1,2,3, Roberto Sacco 4, Annalisa Coviello 1, 
Rossella Ventura 1,2, Stefano Puglisi-Allegra 5, Laura Turriziani 6 and Antonio M. Persico 6,* 
1 Department of Psychology and Centro "Daniel Bovet", Sapienza University of Rome, I-00185 Rome, Italy; 
tiziana.pascucci@uniroma1.it (T.P.); marco.colamartino89@gmail.com (M.C.); elenafiori@hotmail.it (E.F.); 
lisax89@yahoo.it (A.C.); rossella.ventura@uniroma1.it (R.V.) 
2 IRCCS Fondazione Santa Lucia, I-00143 Rome, Italy 
3 European Brain Research Institute EBRI, I-00161 Rome, Italy 
4 Service for Neurodevelopmental Disorders & Laboratory of Molecular Psychiatry and Neurogenetics, 
University “Campus Bio-Medico”, I-00128 Rome, Italy; r.sacco@unicampus.it 
5 IRCCS Neuromed, I-86077 Pozzilli (IS), Italy; s.puglisiallegra@gmail.com 
6 Interdepartmental Program “Autism 0-90”, “Gaetano Martino” University Hospital, University of Messina, 
I-98125 Messina, Italy; turrizianilaura@gmail.com 
* Correspondence: apersico@unime.it 
Received: 12 March 2020; Accepted: 9 April 2020; Published: 13 April 2020 
Abstract: Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder 
characterized by deficits in social interaction/communication, stereotypic behaviors, restricted 
interests, and abnormal sensory-processing. Several studies have reported significantly elevated 
urinary and foecal levels of p-cresol in ASD children, an aromatic compound either of environmental 
origin or produced by specific gut bacterial strains. Methods: Since p-cresol is a known uremic toxin, 
able to negatively affect multiple brain functions, the present study was undertaken to assess the 
effects of a single acute injection of low- or high-dose (1 or 10 mg/kg i.v. respectively) of p-cresol in 
behavioral and neurochemical phenotypes of BTBR mice, a reliable animal model of human ASD. 
Results: P-cresol significantly increased anxiety-like behaviors and hyperactivity in the open field, 
in addition to producing stereotypic behaviors and loss of social preference in BTBR mice. Tissue 
levels of monoaminergic neurotransmitters and their metabolites unveiled significantly activated 
dopamine turnover in amygdala as well as in dorsal and ventral striatum after p-cresol 
administration; no effect was recorded in medial-prefrontal cortex and hippocampus. Conclusion: 
Our study supports a gene x environment interaction model, whereby p-cresol, acting upon a 
susceptible genetic background, can acutely induce autism-like behaviors and produce abnormal 
dopamine metabolism in the reward circuitry. 
Keywords: autism spectrum disorder (ASD), biomarker; p-cresol; mouse social behavior; dopamine 
 
1. Background 
Autism Spectrum Disorder (ASD) is a neuropsychiatric disorder that begins early in childhood 
and is characterized by deficits in social interaction and communication, repetitive behaviors, 
restricted interests, and abnormal sensory processing [1]. The incidence of ASD has dramatically risen 
during the last few decades, reaching the rate of 1 affected in 58 children [2], making autism one of 
the most widespread disorders in child neuropsychiatry [3,4]. Both genetic and environmental factors 
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contribute to the pathogenesis of ASD [5,6]. A wide variety of environmental factors have been 
hypothesized to contribute to ASD pathogenesis, but conclusive evidence has been reached for a 
small minority, including prenatal infections, some medications (valproic acid, thalidomide, 
misoprostol, selective serotonin reuptake inhibitors), pesticides, and air pollutants, among others [7]. 
The complexity of ASD has spurred interest into patient subgrouping strategies, either based on 
endophenotyping or on biomarkers. Endophenotypes represent familial, heritable and quantitative 
traits associated with a complex disorder [8,9]. Biomarkers are associated with the disease without 
necessarily displaying heritability and familiarity; rather, they merely tag for the presence/absence of 
the disease due to environmental or pathophysiological links, not necessarily of a genetic nature [9]. 
A reliable set of autism biomarkers could foster earlier and more reliable diagnoses, predict 
developmental trajectories and treatment response, and identify individuals at high-risk, eventually 
leading to the establishment of preventive health care strategies, contributing to dissect ASD into 
more discrete clinical entities, and perhaps even revealing unknown causes of autism, at least in some 
cases [9]. 
In recent years, targeted and unbiased metabolomic studies have unveiled a set of potential ASD 
biomarkers, i.e., small urinary molecules significantly elevated in autistic children [10,11]. Among 
urinary solutes, p-cresol was found to be significantly elevated in autistic children compared to sex- 
and age-matched controls up until age 8, in two independent samples recruited in Italy and France 
[12,13]. This finding was later replicated measuring foecal p-cresol levels [14,15]. Using an unbiased 
approach, mass spectrometry-based urinary metabolomics detected p-cresol among the 20 solutes 
best able to differentiate small ASD children from matched controls [11]. Interestingly, elevated 
urinary p-cresol levels were significantly associated with chronic constipation in autistic children, 
pointing toward slow intestinal transit time as one the main factors allowing greater gut absorption 
of potentially neuroactive compounds, such as p-cresol [16]. The identification of p-cresol and of its 
metabolite p-cresylsulphate as two well-known neuroactive uremic toxins poses the question 
whether, aside from representing a potentially valuable biomarker, the consistent elevation of urinary 
p-cresol detected in young autistic children with chronic constipation may contribute to the clinical 
severity of their ASD [17]. Preliminary data point toward possible correlations between urinary p-
cresol concentrations and ASD severity measured using the Childhood Autism Rating Scale (CARS) 
[12]. Multiple mechanisms could account for the negative influences of p-cresol on neural function, 
ranging from membrane depolarization and increased susceptibility to seizures [18], to decreased 
Na+-K+ ATPase activity [19], to blunted conversion of dopamine (DA) to norepinephrine (NE) due to 
inhibition of dopamine--hydroxylase [20]. 
The studies summarized above spur interest into testing p-cresol for behavioral effects in animals 
carrying a genetic predisposition toward autism-like behaviors. Despite several difficulties in 
developing rodent models with autistic features [21,22], to date, environmental, genetic, and lesion 
murine models reproducing autism-like behaviors have been developed [22–26]. The present study 
aims to assess the effects of acute p-cresol in a well-established inbred murine model of ASD, the 
BTBR mouse [23,27,28]. A single low dose of p-cresol (1 mg/kg) significantly raises anxiety and 
hyperactivity, two frequent ASD comorbidities, while acute administration of a higher dose (10 
mg/kg i.v.) also exacerbates core symptoms of ASD, blunting interest in a conspecific intruder and 
enhancing stereotypic behaviors. Brain region-specific neurochemical analyses link these behaviors 
to parallel, dose-dependent increases in DA turnover in the AMY, nucleus accumbens (NAc) and 
dorsal caudate putamen (CP).  
2. Methods 
2.1. Animals 
Every precaution was taken to minimize animal suffering and the number of animals used. For 
this study, only BTBR T+tf/J male mice were used. Parental strains were obtained from the Jackson 
Laboratories (Bar Harbor, ME, USA). After weaning at postnatal day (PND) 28, animals were housed 
4 per standard breeding cage with food and water ad libitum on a 12:12 h dark:light cycle (lights on 
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07:00 am – 07:00 pm). Only male mice were included in the study to avoid possible variability, due 
to hormonal fluctuations in female mice. Behavioral experiments were carried at PND 60–70 and 
were performed on the second part of the day (h 01:00 pm - 06:00 pm). Behavioral tests were 
performed blind to treatment. Mice were habituated to the behavioral testing room for 1 hour before 
starting the experiment. Tests were conducted in a sound-attenuated room and recorded through a 
camera (SSCDC378P, Sony, Tokyo, Japan) connected to a computer. Video were analyzed using the 
EthoVision video tracking software and the Observer XT program (Noldus information technology, 
Wageningen, The Netherlands) for automatic and manual recording, respectively.  
All groups (CNTR, PC1 and PC10) were submitted to the elevated plus maze, open field motor 
test, object recognition test [29], and three-chamber social interaction test [30,31], in this order. 
Behavioral testing was performed 15 min after receiving a p-cresol/saline injection. Animals were 
sacrificed by rapid decapitation 100 min after the injection, heads were frozen and brains were 
removed and prepared for biochemical assay [32,33]. 
All experiments of this study were approved by the ethics committee of the Italian Ministry of 
Health and therefore conducted under license/approval ID #: 10/2011-B, according with Italian 
regulations on the use of animals for research (legislation DL 116/92) and NIH guidelines on animal 
care. 
2.2. P-cresol Treatment 
P-cresol was purchased from Sigma-Aldrich (St. Louis, MO, USA), dissolved in saline (0.9 % 
NaCl) and the two different doses (1 or 10 mg/kg) were intravenously delivered by tail vein injection 
through a micro-cannula to reduce the stress of manipulation. Mice were randomly assigned to 
experimental groups: (a) naïve, (b) saline-treated controls, and (c) animals that received p-cresol 1 
mg/kg (P-C1) or (d) p-cresol 10 mg/kg (P-C10). Since no difference was recorded between naïve and 
saline-treated animals, they were grouped together and defined as “control group" (CNTR). Behavior 
was tested 15 min after the injection. 
2.3. Elevated Plus Maze  
Emotional reactivity and anxiety-like behaviors were measured using the Elevated Plus Maze, a 
gray plexiglass apparatus with two open arms (27 × 5 cm) and two enclosed arms (27 × 5 × 15 cm) 
extending from a central platform (5 × 5 cm).  
Animals were individually tested for 5 min, and the total number of entries in the open and 
closed arms, the percentage of entries in the open arms [(open entries/open + closed entries) × 100] 
and percentage of time spent in the open arms [(time in open arms/time in open + closed arms) × 100] 
were automatically analyzed using the EthoVision software. 
2.4. Open Field Test  
The apparatus consists in a circular open field, 60 cm in diameter and 20 cm in height. Mice were 
individually introduced in the empty apparatus and left free to explore the arena for 30 min. Videos 
from each 30-min Open Field Test session were recorded. Distance travelled (cm) and speed (cm/s) 
were automatically analyzed using the EthoVision software.  
2.5. Object Recognition Test  
The apparatus is the same as for the Open Field Test (Figure 1C). Each mouse was individually 
submitted to three 6-minute sessions (Open Field, Pre-Test and Test sessions). At the end of each 
session, the animal was returned to its home cage for 3 min. All sessions were videotaped and 
analyzed by an experimenter trained to the Noldus Observer XT event coding software. 
During the Open Field session, each mouse was left free to explore the arena for 6 min and time 
spent grooming was measured. 
During the pre-Test session, the mouse was introduced in the arena containing two identical 
objects (A1 and A2: two identical black plastic cylinders of 8 cm in height and 4 cm in diameter, 
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horizontally fixed to a rectangular base), as shown in Figure 1C, and left free to explore. Total time 
spent exploring two identical objects (A1 and A2) was measured and analyzed. 
For the Test session, both objects were substituted, one with object A3, identical to the previous 
objects, and the other with the new object B (a red and gray plastic spool: 8 cm in height and 5 m in 
diameter). Object recognition was evaluated by comparing total time spent exploring the novel (B) 
vs. the familiar (A3) object.  
 
Figure 1. P-cresol enhances anxiety-like behaviors, stereotypies, locomotor parameters and hinders 
social preference in BTBR mice. (A) Total entries, % of time spent and entries in open arms in the 
Elevated Plus Maze. (B) Distance travelled and speed in the Open Field Test after acute p-cresol 
treatment. (C) Schematic representation of the Object Recognition Test. (D) Time spent grooming 
during the first session of the Object Recognition Test. (E) Time spent exploring the novel or familiar 
object during the test session of the Object Recognition Test. (F) Schematic representation of the three-
chamber Social Interaction Test. (G) Time in object and subject zones during the Social Interaction 
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Test session. (H) Time spent in contact with the object or with the social intruder during the Social 
Interaction Test. Results are shown as mean ± sem. *, **, *** p < 0.05, p < 0.01, p < 0.001 P-C1 or P-C10 
vs. CNTR. ^^ p < 0.01 P-C10 vs. P-C1, ## p < 0.01 old vs. new, §§, §§§ p < 0.01, p < 0.001 subject vs. object. 
2.6. Three-chamber Social Interaction Test  
The apparatus was a three-chamber box made in plexiglass (Figure 1F). Two transparent 
partitions (23 cm in height) with removable openings divided the box into three identical rectangular 
chambers (60 cm × 40 cm). The two external chambers contained two perforated plexiglass cylinders, 
used to enclose stranger BTBR mice. The test consisted in two 10 min sessions, encompassing the 
Habituation session and the Sociability Test session. Immediately after the Habituation session the 
animal was confined to the center chamber while an unfamiliar strain-, sex-, and age-matched adult 
intruder (subject) or an object were placed inside the cylinders. Videos were recorded and analyzed 
both automatically and manually, using the EthoVision and Observer XT programs. Time spent in 
each chamber, time spent in contact with the two cylinders, distance travelled and speed were 
recorded and analyzed. 
2.7. Biochemical Assay 
Biochemical assays were performed as previously described [32,33]. Briefly, frozen brains were 
fixed vertically on the freezing microtome pate. Punches were obtained from 300 m-thick brain slices 
(coronal sections). Stainless steel tubes of 0.8, 1.0, or 1.5 mm inside diameter were used. Coordinates 
were measured as follows: medial pFC, two slices from section 80 to section 130 (1.5 mm tube); NAc, 
three slices from section 151 to section 201 (1.0 mm tube); CP, 4 slices from section 151 to section 230 
(1.5 mm tube); AMY, 5 slices from section 251 to section 350 (0.8 and 1.0 mm tube); HIP, 3 slices from 
section 301 to section 350 (0.8 and 1.0 mm tube; including CA1, CA2 and CA3 fields). Punches were 
stored in liquid nitrogen until the day of analysis. Frozen tissues were then weighed and 
homogenized in 0.05 M HClO4. Homogenates were centrifuged at 14,000 rpm for 20 min at 4 °C. 
Tissue levels of DA, NE, 5-HT and their metabolites were assessed using HPLC. The HPLC system 
consists of an Alliance (Waters) system and a coulometric detector (ESA Model 5200A Coulochem II) 
provided with a 5011 high sensitivity analytical cell and a 5021 conditioning cell, the potential being 
set at 0.450 mV and 0.100 mV, respectively. A Nova-Pack Phenyl column and a Sentry Guard Nova-
Pack pre-column were purchased from Waters Assoc. Flow rate was 1 ml/min. The mobile Phase 
consisted of 3% methanol in 0.1 M Na-phosphate buffer pH 3.0, 0.1 mM, Na2EDTA and 0.5 mM 1-
octane sulphonic acid Na salt.  
2.8. Statistical Analysis 
Behavioral parameters recorded in the Elevated Plus Maze and Open Field Test were analyzed 
using one-way ANOVAs to detect group effects (three levels: CNTR, P-C1, P-C10), followed by a 
post-hoc Duncan’s test. For the Object Recognition Test, the total time spent exploring the familiar 
(A3) vs. the novel (B) object during the test session were analyzed by two-way ANOVA for repeated 
measures (“group”, three levels: CNTR, P-C1, P-C10 as between factor; “object”, two levels: A3 and 
B as within factor). Simple effect analysis of the factor “object” was also performed within each group. 
Similarly, for the Social Interaction Test time spent in each chamber and time spent in contact with 
the two cylinders were analyzed by two-way ANOVA for repeated measures (“group” three levels: 
CNTR, P-C1, P-C10 as between factor; “zone”, two levels: object and subject as within factor). 
Distance travelled and speed by treatment group were analyzed using one-way ANOVA, followed 
by Duncan’s post-hoc test. Data are presented as mean ± sem.  
One-way ANOVAs, followed by a post-hoc Duncan’s test, were used for statistical analysis of 
the effects of treatment (three levels: CNTR, P-C1, P-C10) for each amine and metabolite (ng/g wet 
weight) within each brain region. 
3. Results 
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3.1. P-cresol Enhances Anxiety-like Behaviors in BTBR Mice 
The Elevated Plus Maze test is based on the natural inclination of mice to avoid open, elevated 
and bright places, in spite of their tendency to actively explore novel environments. Results are 
shown in Figure 1A (CNTR, n = 10; P-C1, n = 8; P-C10, n= 8 mice). The percentage of time spent in the 
open arms by the CNTR group (17.13%) is consistent with previous studies [34]. P-cresol (1 and 10 
mg/kg) profoundly decreases the percentage of time spent in the open arms (F2,23 = 10.632; p < 0.001), 
without significantly affecting the total number of entries (F2,23 = 1.187; p = 0.32) and the percentage of 
entries in the open arm (F2,23 = 1.644; p = 0.21). Hence, both low and high p-cresol doses increase 
anxiety-like behaviors in BTBR mice tested using the Elevated Plus Maze. 
3.2. Locomotor Activity is Enhanced by p-cresol in the Open Field Test 
Results from the Open Field Test are displayed in Figure 1B (CNTR, n = 10; P-C1, n = 9; P-C10, n 
= 7). Both low- and high-dose p-cresol significantly enhanced distance travelled (F2,23=5.826; p<.01) 
and speed (F2,23 = 5.914; p < 0.01) compared to control mice, already yielding hyperactivity at low p-
cresol doses. 
3.3. P-cresol Enhances Motor Stereotypies without Modifying Object Recognition and Discrimination 
Behaviors 
During the first Object Recognition Test session (Figure 1C), time spent grooming was measured 
(CNTR, n = 8; P-C1, n = 7; P-C10, n = 7). Figure 1D shows that the P-C10 group spent significantly 
more time self-grooming compared with controls and P-C1 animals (F2,19 = 18.12; p < 0.001), who do 
not differ from each other. A partial dose-dependent shift from hyperactivity to stereotyped 
behaviors was thus recorded. 
Time spent exploring two identical objects during the Pretest session of the Object Recognition 
Test did not differ between controls and treatment groups (mean ± sem: CNTR = 80.27 ± 6.59; PC-1 = 
88.09 ± 6.25; PC-10 = 67.55 ± 11.92; F2,23 = 1.426 p = 0.264, data not shown), demonstrating unchanged 
interest in object exploration. Similar results were obtained during the Test session (Figure 1E), 
indicating that p-cresol does not significantly influence the ability to discriminate novel vs. familiar 
objects (F2,19 = 0.897; p = 0.424). 
3.4. High Dose p-cresol Thwarts Preference for Social Interaction 
Behavioral results from the three-chamber Social Interaction Test are displayed in Figure 1G,H 
(CNTR, n = 6; P-C1, n = 7; P-C10, n = 7). No treatment effect was recorded on general motor activity 
neither during the habituation session (distance travelled: F2,16 = 3.342; p = 0.054; speed: F2,16 = 1.544; p 
= 0.237; time spent in each chamber: F2,16 = 0.276; p = 0.763), nor during the Sociability Test session 
(distance travelled, F2,16 = 1.504; p = 0.243; speed: F2,16 = 1.572; p = 0.229; time spent in each chamber F2,16 
= 0.164; p = 0.85) (Figure 1G). Time spent sniffing the cylinders did not differ during habituation (F2,16 
= 0.263; p = 0.77), whereas a significant treatment effect was recorded during the Sociability Test over 
time spent in contact with the cylinders containing subject vs. object (F2,16 = 6.241; p < 0.01). In fact, 
CNTR and low-dose cresol-treated animals (P-C1) maintained a significant preference for the social 
stimulus, while high-dose cresol-treated animals (P-C10) lost their social preference, spending the 
same amount of time sniffing the two cylinders containing either the conspecific intruder or the object 
(Figure 1H). 
3.5. P-cresol Enhances Dopamine Metabolism in NAc, CP and AMY 
Neurochemical data concerning brain levels of monoamines and their metabolites assessed in 
medial pFC, HIPP, AMY, CP and NAc are summarized in Table 1 and Figure 2 (CNTR, n = 9; P-C1, n 
= 6; P-C10, n = 6). Significant treatment effects were recorded in NAc, CP and AMY on levels of DA 
(NAc F3,18 = 21.358; p < 0.001; CP: F3,15 = 13.028; p < 0.001; AMY: F3,15 = 3.267; p < 0.05), HVA (CP: F3,15 = 
8.988; p < 0.001; NAc: F3,18 = 6.649; p < 0.01), and DOPAC (NAc: F3,18 = 9.886; p < 0.001; CP: F3,15 = 5.851; 
p < 0.001; AMY: F3,15 = 3.482; p < 0.05) (Figure 2B). DA turnover was largely enhanced in NAc and CP 
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and only by high-dose p-cresol (P-C10); whereas in AMY, both low- and high-dose p-cresol were 
equally effective (Figure 2B). No significant change was recorded for norepinephrine and 5-HIAA, 
whereas 5-HT levels were increased only in the CP following the higher dose of p-cresol (F2,16 = 8.927; 
p < 0.01) (Table 1). No treatment effect was detected in medial pFC and HIPP for any monoamine or 
metabolite level (Table 1).  
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Table 1. Neurochemical analysis of monoamine and metabolite levels (ng/g wet weight) assessed in medial prefrontal cortex, hippocampus, amygdala, caudate 
putamen and nucleus accumbens. 
  DA DOPAC HVA NE 5HT HIAA 
pFC 
CNTR 342,95±99,78 44,96±9,21 43,95±7,91 179,12±26,24 826,28±116,29 266,67±51,36 
P-C1 305,53±57,11 43,79±11,19 37,07±6,91 132,30±25,35 607,64±74,63 152,62±15,13 
P-C10 423,87±138,8 76,9±24,84 42,91±14,9 139,42±36,39 881,03±207,31 171,06±39,93 
HIPP 
CNTR 155,18±15,24 41,73±15,71 29,98±2,79 n.d. 641,22±173,86 378,98±59,82 
P-C1 113,92±26,27 21,54±7,92 22,77±3,72 n.d. 425,17±92,36 327,61±102,74 
P-C10 119,47±40,91 37,29±12,97 30,65±7,65 n.d. 365,6±145,62 314,2±99,42 
AMY 
CNTR 858,36±112,78 68,98±6,62 57,41±11,05 274,34±103,69 193,46±42,02 149,84±55,3 
P-C1 2292,71±526,75 * 187,95±38,11 * 122,05±26,41 * 314,18±89,95 356,62±109,27 212,38±88,17 
P-C10 2197,45±992,31 * 179,38±30,12 * 140,21±23,75 * 283,15±48,49 330,85±59,27 226,03±36,56 
CP 
CNTR 5284,18±1015,8 584,97±186,65 251,81±33,64 35,46±8,61 159,61±31,77 133,99±28,56 
P-C1 5499,14±842,38 327,32±56,27 240,48±43,35 46,41±8,61 183,88±31,09 130,22±38,39 
P-C10 16270,59±2153,37 ***,### 1176,26±223,34 ***,### 658,32±97,93 ***,### 63,11±12,83 341,1±34,82 **,## 242,73±49,04 
NAc 
CNTR 5623,89±1050,64 506,55±91,15 412,55±87,32 1214,04±390,84 1191,69±355,05 459,72±126,19 
P-C1 5035,05±1134,2 504,3±119,73 276,01±49,36 1359,63±200,81 1232,82±357,02 305,25±63,12 
P-C10 16156,11±1812,97 **,## 1698,82±325,04 **,## 817,35±91,08 *,## 1883,69±626,27 1360,47±512,3 480,62±189,73 
Data are shown as mean ± sem. Highlighted in bold, significant effects of group x amine or metabolite.  CNTR, n = 9; P-C1, n = 6; P-C10, n = 6.  
*, **, ***p < 0.05, 0.01, 0.001 P-C1 or P-C10 vs. CNTR. #, ##, ### p < 0.05, 0.01, 0.001 P-C10 vs. P-C1. 
 
Brain Sci. 2020, 10, 233 9 of 16 
  
 
Figure 2. P-cresol enhances tissue levels of dopamine and its metabolites in the amygdala, caudate 
putamen and nucleus accumbens of BTBR mice. (A) Tissue levels of DA, DOPAC, HVA, NE, 5-HT 
and 5-HIAA, measured in medial pFC, NAc, CP, HIP, AMY. (B) Tissue levels of DA, DOPAC, HVA, 
measured in NAc, CP and AMY. CNTR, n = 9–10; P-C1, n = 6, P-C10 n = 6. Data are expressed as mean 
± sem ng/g wet weight. *, **, *** p < 0.05, 0.01, 0.001 P-C1 or P-C10 vs. CNTR group. ##, ### p < 0.01, 0.001 
P-C10 vs. P-C1 (treatment effect) by Duncan’s post-hoc test following one-way ANOVAs. 
Abbreviations: AMY: Amygdala; CP: Caudate Putamen; DA: dopamine; DOPAC: 3,4-
Dihydroxyphenylacetic acid; HIP: Hippocampus; HVA: Homovanillic acid; NAc: Nucleus 
Accumbens; pFC: preFrontal Cortex. 
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4. Discussion 
In the present study, acute p-cresol administration to BTBR mice, a reliable animal model of ASD 
[23,27,28], elicited autism-like behaviors and enhanced dopaminergic turnover both in the AMY, and 
in the dorsal and ventral striatum. Importantly, behavioral abnormalities elicited by p-cresol in BTBR 
mice strikingly resemble core symptoms and co-morbid disorders clinically observed in human 
autistic individuals. On the one hand, excessive interest in objects over social interaction and 
stereotypic behaviors represent two of the hallmarks of an ASD diagnosis in humans [1]. 
Additionally, hyperactivity and anxiety are among the most frequent co-morbidities in autistic 
patients, with ADHD and anxiety disorders being diagnosed in 33%–37% and in 39.6% of ASD cases, 
respectively [35,36]. BTBR mice are an inbred strain spontaneously displaying autism-like behaviors 
[23,27,28]. These behavioral abnormalities likely stem from strain-specific genetic underpinnings 
involving neurodevelopmental genes, like kynurenine 3-hydroxylase (Kmo), Disrupted in 
Schizophrenia (Disc1) and exostosin 1 (Ext1) [28]. The induction of hyperactivity in the Open Field 
Test, but not in the 3-chamber Social Interaction Test, most likely represents only an apparent 
contradiction, because the more interesting social interaction apparatus is able to engage motivated 
exploratory behaviors in mice that can “cover” the spontaneous hyperactivity visible in the Open 
Field Test. In addition, differences in session duration between the two tests (30 min in the Open Field 
Test vs. 10 minutes in the Social Interaction Test) can further influence the expression of hyperactivity 
in treated BTBR. Instead, a large body of literature reports a lack of sociability in BTBR using the 
three-chambered social approach, although data showing that BTBR control mice display significant 
sociability [37–40] or a non-significant preference for subject exploration are also present (see Figure 
1B in ref. [40], Figure 3B in ref. [41], and Figure 3B in ref. [42]). One possible explanation for these 
discrepancies is that genetically-driven ASD-like behaviors in the BTBR strain may spontaneously be 
under threshold and may emerge to a different extent depending upon experimental manipulations, 
handling or treatments [37]. Furthermore, discrepancies due to different choice of intruder 
(conspecific vs. different strain) in the Social Interaction Test cannot be excluded (in present study we 
used a BTBR conspecific intruder). Baseline control behavioral parameters recorded in our BTBR mice 
in the Elevated Plus Maze, Object Recognition Test and Social Interaction Test are absolutely in line 
with previous studies from our lab [29,32,43,44] and are coherent with the overall literature [45–47], 
although absolute values predictably differ, likely due to differences in housing environment, animal 
handling, and test settings. Finally, blunted social preference in the three-chamber test could 
conceivably stem from enhanced anxiety rather than reflecting a real social interaction deficit. While 
we cannot exclude contributions by anxiety to this behavior, the emotional reaction of BTBR mice to 
the objects during pre-test and test sessions of the Object Recognition Test did not differ between 
groups, as all groups spent the same time exploring objects. Most importantly, both low- and high-
dose p-cresol produced anxiety-like behaviors in the Elevated Plus Maze. Therefore, if anxiety played 
a pivotal role in reducing social preference, the lower p-cresol dose should have also been effective. 
In summary, our results collectively support a gene x environment interaction model, whereby, 
acting upon a susceptible genetic background, p-cresol triggers anxiety and hyperactivity at a low 
dose, while boosting core autism-like symptoms at the higher dose. 
Behavioral abnormalities are paralleled by neurochemical alterations, mainly involving the 
dopaminergic turnover. This interpretation is in line with long-standing evidence of dopamine--
hydroxylase inhibition by p-cresol [20] and with the proportionate increase in DA and its metabolites, 
supporting increased DA accumulation, release and catabolism (both intra- and extra-cellular). 
However, the measurable, albeit non-significant, increase in NE recorded in several brain regions 
displaying increased DA and its metabolites (Table 1) indicates that enhanced DA synthesis may also 
contribute to cresol-induced dopaminergic imbalance. On the one hand, levels of DA and its 
metabolites were dose-dependently increased in the ventral and dorsal striatum, where only the 
higher p-cresol dose was effective (Figure 2B). On the other hand, dose-independent effects were 
recorded in the AMY, where low- and high-dose p-cresol were equally effective in boosting DA 
turnover (Figure 2B). This regional distribution and dose-dependency fit well with the pattern of 
behavioral abnormalities recorded in these same animals. Low- and high-dose p-cresol were equally 
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effective in reducing time spent in the open arms at the Elevated-Plus Maze and in enhancing 
locomotor activity (Figure 1A,B). Instead, only high-dose p-cresol significantly increased stereotypic 
behaviors and blunted social interaction (Figures 1D,H). This trend resembles the effects of acute 
amphetamine in rodents, yielding hyperactivity at low doses and stereotypic behaviors (sniffing and 
grooming) at higher doses [48,49]. Drosophila melanogaster carrying the ASD-associated hDAT 
ΔN336 variant, which impairs DA uptake while sparing DA efflux, displays behavioral abnormalities 
that are strikingly overlapping with those recorded here following acute p-cresol—namely increased 
fear, impaired social interactions, and enhanced locomotion [50]. Modest increases in 5-HT levels 
parallel the much larger changes observed in levels of dopamine and its metabolites (Table 1). We 
cannot exclude synergistic serotoninergic contributions to cresol-induced behavioral effects, since 5-
HT transporter KO mice display at least some autism-like behaviors, including social deficits and 
increased anxiety [51]. However, changes in brain 5-HT levels are relatively minor compared to 
changes in DA and never reach statistical significance, except in the striatum following high-dose p-
cresol (Table 1). Furthermore, changes in 5-HIAA levels are even more modest, and there is only 
partial overlap between serotoninergic neurochemical parameters and behavioral changes. 
Collectively, serotoninergic contributions to cresol-induced behavioral abnormalities may seemingly 
play a secondary role at best. Instead, our data strongly reinforce the “dopamine hypothesis” of ASD 
[52], pointing toward the existence in autistic brains of two distinct dopaminergic activation 
thresholds: a lower threshold in the AMY to boost anxiety and hyperactivity, and a higher threshold 
in ventral and dorsal striatum to produce stereotypic behaviors and to divert motivational drives 
from interaction with conspecific animals to inanimate objects. D1 receptor activation or D2 receptor 
knock-out in the dorsal striatum have been shown to yield autistic-like behaviors in mice [53]. In line 
with this evidence, BTBR mice display blunted DRD2 signaling and responsiveness to extracellular 
DA in the presence of preserved DRD2 mRNA and protein levels [54]. On the other hand, comparable 
DRD1 expression and responsiveness to DA was recorded in BTBR and in C57Bl6 mice [54]. 
Altogether, much of the current literature on the motivational circuitry in ASD underscores reward-
processing deficits towards social and monetary incentives [55,56]. Instead, results displayed in 
Figure 1H promote a more balanced view, whereby reduced DA activation by social stimuli may be 
seemingly paired with preserved or even enhanced DA activation by exposure to inanimate objects 
or by sensory self-stimulation [57–59]. Future experiments will have to extend the present findings, 
identifying the receptor and signaling pathways mediating the dopaminergic effects recorded in our 
experiments, and to explore whether the activation of DA turnover by p-cresol contributes to favoring 
LTP-based synaptic plasticity in the NAc [60], possibly fostering “addictive” attitudes towards 
routines, objects, or absorbing interests including internet and videogames. 
Urinary and foecal levels of p-cresol have been consistently found elevated in autistic children 
compared to typically developing controls [11–16]. Preliminary evidence suggests that high urinary 
p-cresol may be clinically associated with greater autism severity and history of behavioral regression 
[12,17]. P-cresol is not produced by human cells, which lack p-hydroxyphenylacetate decarboxylase 
(pHPAD), the final enzyme of tyrosine transformation into p-cresol [17]. Hence, urinary p-cresol is 
either absorbed through the skin, the gut and the lungs from a variety of environmental sources 
(listed in Table 2 in ref. [17]), or it is produced by gut bacterial strains able to express pHPAD. The 
primary origin of urinary p-cresol elevation in autistic children remains to be determined, as does the 
reason for its normalization after age 8. However, its association with chronic constipation and longer 
intestinal transit time supports greater p-cresol absorption through the gut, while no association with 
the “leaky gut” was observed [16]. Chronic constipation thus likely represents a broad, non-specific 
facilitator of neurotoxic effects exerted by environmental and gut-derived compounds. 
The present results raise further interest into p-cresol, not only as an ASD biomarker but also as 
a potential contributor to autism pathogenesis, by boosting DA turnover in specific brain regions of 
autistic individuals. P-cresol is certainly not the only neuroactive exogenous compound produced by 
gut bacteria and able to negatively affect behavior. Propionic acid, a short chain fatty acid produced 
by anaerobic gut bacteria including Clostridia and Propionibacteria, has been shown to produce a 
variety of behavioral, immune, mitochondrial effects in rodent models closely resembling human 
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ASD [61]. Studies of urinary and foecal levels of propionic acid in autistic children compared to 
typically developing controls have yielded conflicting results [14,15]. Nonetheless, this compound 
could indeed play a pathoplastic role in specific patient subgroups, which need to be better defined 
at the clinical level. Meanwhile, additional tryptophan-derived gut bacterial compounds were found 
significantly elevated in the urines of autistic children, namely indolyl 3-acetic acid, indoxyl sulfate, 
and indolyl lactate [11]. These compounds have not yet been thoroughly assessed for possible 
neuroactive behavioral effects. 
5. Limitations 
The main limitation of the present study is the lack of a reversal experiment, showing that 
abnormal behaviors are corrected by administering dopamine receptor antagonists. Due to practical 
constraints, sample sizes of BTBR mice are relatively small, but 4–5 different litters were used for 
behavioral experiments and behavioral data appear reasonably consistent among different litters. In 
fact, all significant differences between control vs. cresol-treated animal mean values displayed in 
Figure 1 are at least three times larger than inter-litter S.E.M.s per each sample, with the sole exception 
of the Social Interaction Test (object vs. subject contact time) were P-C10 and controls differ 2.47 times 
the interlitter S.E.M. values of controls. Repetitive behaviors/restricted interests were assessed only 
by measuring stereotypic motor activity in the open field test, and not by applying specific tests 
designed to quantify mouse behaviors corresponding more closely to this diagnostic criterion. 
Locomotor activity data could have provided additional information if broken down into bins of 3–
5 min, allowing an assessment of how quickly the mice habituate to the open field, and the time 
course of p-cresol effects. Finally, urinary baseline levels of endogenous p-cresol should be measured 
and compared among different inbred mouse strains because, if particularly elevated in BTBR mice, 
they could promote their autism-like phenotypic features and contribute to the behavioral 
abnormalities induced by exogenous p-cresol administration. In addition to addressing these 
limitations, our follow-up study will involve in parallel both the hypersociable C57Bl/6 mice and the 
ASD model BTBR mice, to further test the hypothesis that the behavioral abnormalities exacerbated 
by acute p-cresol are the result of a BTBR-specific gene x environment interaction.  
6. Conclusions 
This study demonstrates that acute p-cresol administration to an animal model of ASD induces 
behavioral abnormalities closely resembling core symptoms of ASD and comorbidities frequently 
observed in autistic individuals. These results underscore the importance of gene x environment 
interaction models, able to merge genetic predisposition and evidence-based environmental 
exposure to specific neurotoxic compounds into a unitary scenario. From a mechanistic standpoint, 
these results move the field beyond well-established paradigms in the autism literature, such as the 
imbalance between glutamate and GABA to explain insistence on sameness and the co-morbidity 
with epilepsy [62], or the role of 5-HT in reference to hyperserotonemia, disruption of circadian 
rhythmicity, neuroinflammation and neuronal excitability [63–65]. In a complementary view, they 
point toward critical dopaminergic roles in autistic symptoms as being relevant as stereotypic 
behaviors, hyperactivity, anxiety and motivational drive towards inanimate objects. Thirdly, urinary 
gut-derived neurotoxic compounds, such as p-cresol, could serve as useful ASD biomarkers, whose 
specificity now deserves to be assessed in samples of young non-autistic children affected with 
chronic constipation.  Finally, the correction of chronic constipation and microbiota transfer therapy 
represent two reasonable and testable approaches, aimed at partly ameliorating autistic behaviors by 
reducing the absorption of neurotoxic compounds of environmental origin or derived from specific 
gut-bacterial strains [66]. Studies addressing the efficacy of these therapeutic approaches will largely 
benefit from parallel assessments of urinary biomarkers, such as p-cresol and other gut-derived 
compounds, in order to provide mechanistic insights into their effects on the longitudinal time course 
of autistic symptoms.  
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